List of Excipients in Branded Drug TRANSMUCOSAL FENTANYL CITRATE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
HJ Harkins Company Inc	TRANSMUCOSAL FENTANYL CITRATE	fentanyl citrate	52959-549	CITRIC ACID
HJ Harkins Company Inc	TRANSMUCOSAL FENTANYL CITRATE	fentanyl citrate	52959-549	DEXTRATES
HJ Harkins Company Inc	TRANSMUCOSAL FENTANYL CITRATE	fentanyl citrate	52959-549	MAGNESIUM STEARATE
HJ Harkins Company Inc	TRANSMUCOSAL FENTANYL CITRATE	fentanyl citrate	52959-549	MODIFIED CORN STARCH
HJ Harkins Company Inc	TRANSMUCOSAL FENTANYL CITRATE	fentanyl citrate	52959-549	SODIUM PHOSPHATE, DIBASIC

Excipient Strategy and Commercial Opportunities for Transmucosal Fentanyl Citrate

Last updated: February 28, 2026

Transmucosal fentanyl citrate is a potent opioid used for managing breakthrough pain in patients with chronic cancer pain who are opioid-tolerant. Its administration via mucous membranes requires specific excipient formulations to optimize bioavailability, stability, and patient compliance.

What Is the Current Excipient Strategy?

Key Formulation Components and Functions

• Rapid-dissolving film or lozenge base: Usually includes hydroxypropyl methylcellulose (HPMC) or carboxymethyl cellulose, ensuring fast dissolution and mucosal absorption.
• Sweeteners: Mannitol and sorbitol are common, masking bitterness and improving patient compliance.
• Flavoring agents: Mint or citrus flavorings enhance palatability.
• Preservatives: Sodium benzoate or parabens extend shelf life but are minimized to reduce irritation.
• Permeation enhancers: Agents such as sodium taurocholate increase mucosal absorption efficiency.
• pH modifiers: Citric acid or sodium citrate optimize fentanyl's stability and absorption.

Stabilizing excipients

• Antioxidants: Ascorbic acid or tocopherols minimize oxidation risks.
• Humectants: Glycerol or propylene glycol help maintain moisture, ensuring consistent dissolution.

Delivery-specific considerations

• The formulation must be non-irritating to mucosal tissues.
• It should prevent premature fentanyl degradation.
• The excipient matrix must allow rapid drug release for quick onset of analgesia.

Commercial Opportunities

Market Landscape

• Global Transmucosal Fentanyl Market was valued at approximately USD 360 million in 2022; projected CAGR of 4.8% until 2030 (source [1]).
• Key products include Actiq (oral lozenge), Fentora (buccal tablet), and Subsys (nasal spray).
• Patent expirations over the next five years create opportunities for innovators to introduce formulations with improved excipient compositions.

Innovation Opportunities

• Development of lower irritation excipient systems to enhance patient tolerability.
• Creation of rapid-melt films incorporating novel permeability enhancers for faster onset.
• Use of bio-based or sustainable excipients aligning with regulatory trends.
• Integration of taste-masking excipients compatible with patient preferences.

Regulatory Considerations

• FDA-approved formulations typically specify excipient composition.
• Abuse-deterrent excipients are gaining importance to mitigate misuse.
• New formulations require demonstration of bioequivalence if substituting excipients or delivery platforms.

Strategic Recommendations

• Emphasize permeation enhancers with established safety profiles.
• Optimize sweetener and flavor profiles for diverse patient populations.
• Prioritize stability studies of excipient interactions with fentanyl under various storage conditions.
• Pursue patent protection for novel excipient combinations or delivery systems.

Risks and Challenges

• Potential for mucosal irritation from permeation enhancers.
• Regulatory hurdles surrounding permeation enhancer approval.
• Balancing drug release speed with excipient safety.
• Managing manufacturing complexity of novel delivery systems.

---

Key Takeaways

• Excipient strategies for transmucosal fentanyl citrate center on enhancing absorption, ensuring stability, and improving patient experience.
• The market displays growth potential, especially with product innovations aligned with regulatory and consumer demands.
• Developing formulations with novel permeation enhancers, taste-masking agents, and sustainability considerations can create competitive advantages.
• Patent landscape shifts open opportunities for new excipient combinations, provided safety and efficacy are validated.

---

FAQs

Q1: What are the main challenges in formulating transmucosal fentanyl citrate?

A1: Ensuring rapid absorption without mucosal irritation, maintaining drug stability, and achieving patient-friendly taste and ease of use.

Q2: Which excipients are most critical for absorption enhancement?

A2: Sodium taurocholate and other bile salt derivatives serve as permeation enhancers but require careful safety assessment.

Q3: How does patent expiration influence formulation innovation?

A3: It opens pathways for developing new formulations with distinct excipient profiles, potentially leading to market differentiation.

Q4: Are there safety concerns with permeation enhancers?

A4: Yes. Some enhancers can cause mucosal irritation or toxicity; thorough safety evaluation is mandatory.

Q5: What trends are shaping excipient strategies in this market?

A5: A focus on reducing irritation, improving taste-masking, sustainability, and integrating abuse-deterrent features.

---

References

[1] MarketWatch. (2022). Transmucosal Fentanyl Market Size, Share & Trends. Retrieved from https://www.marketwatch.com